Blood coagulation and fibrinolytic factors in 105 patients with hemorrhagic syndrome caused by accidental contact with Lonomia obliqua caterpillar in Santa Catarina, Southern Brazil

Summary

Haemostatic disorders caused by Lonomia obliqua caterpillars has reached epidemic proportions in southern Brazil. Here we evaluated coagulation and fibrinolysis in 105 patients after accidental contact with Lonomia obliqua caterpillars. Global coagulation tests were prolonged in most cases and patients were divided into 3 groups according to fibrinogen (Fg) level: 0.5 g/l (group A); 0.51–1.5 g/l (group B), >1.5 g/l (group C). There was a significant reduction of factors V, XIII, VIII and prekallikrein in group A, with no change in factors X, II and von Willebrand factor. Thrombin-antithrombin and prothrombin F1+2 were elevated in most patients. Antithrombin and protein S were not changed whereas protein C levels were reduced in group A. Plasminogen and alfa2-antiplasmin levels were significantly reduced in group A and D-Dimer levels were extremely high in all groups, showing that fibrinolysis had been activated, possibly secondary to fibrin production. Levels of t-PA were normal and PAI-1 was mildly elevated in group A. The platelet count remained above 150 × 10⁹ platelets/ml in 97% of cases. In summary, our results suggest that Lonomia obliqua envenoming is characterized by a consumption coagulopathy and secondary fibrinolysis.

Keywords

Lonomia obliqua - envenomation - fibrinolysis - coagulation - DIC

• References

• 1 Arocha-Piñango CL, Layrisse M. Fibrinolysis produced by contact with a caterpillar. Lancet 1969; 7597: 810-2.
• 2 Arocha-Piñango CL, Bosch NB, Torres A, Goldstein C, Nouel A, Argiello A, Carvajal Z, Guerrero B, Ojeda A, Rodriguez A, Rodriguez S. Six new cases of a caterpillar-induced bleeding syndrome. Thromb Haemost 1992; 67: 402-7.
• 3 Kelen EMA, Picarelli ZP, Duarte AC. Hemorrhagic syndrome induced by contact with caterpillars of the genus Lonomia (saturniidae, hemileucinae). J Toxinol Toxin Rev 1995; 14: 283-308.
• 4 Duarte ACL, Crusius PS, Pires CAL, Schilling MA, Fan HW. Intracerebral haemorrhage after contact with Lonomia caterpillars. Lancet 1996; 348: 1033
• 5 Burdmann EA, Antunes I, Saldanha LB, Abdulkader RCMR. Severe acute renal failure induced by the venom of Lonomia caterpillars. Clin Nephrol 1996; 46: 337-9.
• 6 Reis CV, Kelen EMA, Farsky SHP, Portaro FCV, Sampaio CAM, Fernandes BL, Camargo ACM, Chudzinski-Tavassi AM. A Ca⁺⁺ activated serine protease (Lopap) could be responsible for the haemorrhagic syndrome caused by the caterpillar Lonomia obliqua. Lancet 1999; 353: 1942
• 7 Reis CV, Portaro FCV, Andrade SA, Fritzen M, Sampaio CAM, Camargo ACM, Chudzinski-Tavassi AM. A prothrombin activator serine protease from the Lonomia obliqua caterpillars venom (Lopap): biochemical characterization. Thromb Res 2001; 102: 427-36.
• 8 Donato JL, Moreno RA, Hyslop S, Duarte A, Antunes E, LeBonniec BF, Rendu F, Nucci G. Lonomia obliqua caterpillar spicules trigger human blood coagulation via activation of factor X and prothrombin. Thromb Haemost 1998; 79: 539-42.
• 9 Guerrero B, Arocha-Piñango CL. Activation of human prothrombin by the venom of Lonomia achelous (Cramer) caterpillars. Thromb Res 1992; 66: 169-77.
• 10 Amarant T, Burkhart W, Le VineH, Arocha-Piñango CL, Parikh I.. Isolation and complete amino acid sequence of two fibrinolytic proteinases from the toxic saturnid caterpillar Lonomia achelous . Biochim Biophys Acta 1991; 1079: 214-21.
• 11 Spero AJ, Lewis JH, Hasiba U. Desseminated intravascular coagulation findings in 346 patients. Thromb Haemost 1980; 43: 28-33.
• 12 Okajima K, Sakamoto Y, Uchiba M. Heterogeneity in the incidence and clinical manifestations of disseminated intravascular coagulation: A study of 204 cases. Am J Hematol 2000; 65: 215-22.
• 13 Wada H, Yoshihiro W, Nakasaki T, Shimura M, Hiyoyama K, Nagaya S, Mori Y, Shiku H. Outcome of disseminated intravascular coagulation in relation to the score when treatment was begun. Thromb Haemost 1995; 74: 848-52.
• 14 Wada H, Sakuragawa N, Mori Y, Takagi M, Nakasaki T, Shimura M, Hiyoyama K, Nisikawa M, Gabazza EC, Deguchi K, Kazama M, Shiku H. Hemostatic molecular markers before the onset of disseminated intravascular coagulation. Am J Hematol 1999; 60: 273-8.
• 15 Motta G, Rojkjaer R, Hasan AA, Cines DB, Schmaier AH. High molecular weight kininogen regulates prekallikrein assembly and activation on endothelial cells: a novel mechanism for contact activation. Blood 1998; 91: 516-28.
• 16 Motta G, Shariat-Madar Z, Mahdi F, Sampaio CAM, Schamaier AH. Assembly of high molecular weight kininogen and activation of prekallikerin on cell matrix. Thromb Haemost 2001; 96: 840-7.
• 17 Guerrero BA, Arocha-Piñango Cl, San Juan Ag. Lonomia achelous caterpillar venom (LACV) selectively inactivates blood clotting factor XIII. Thromb Res 1997; 87: 83-93.
• 18 Guerrero BA, Arocha-Piñango Cl, San Juan Ag. Degradation of human factor XIII by Lonomin V, a purified fraction of Lonomia achelous caterpillar venom. Thromb Res 1997; 87: 171-81.
• 19 Zuch A, Kloczko J, Bielawiec M, Mysliwiec M, Grabowski R, Buluk K. Fibrin stabilizing factor (factor XIII) consumption as an indica- tor of disseminated intravascular coagulation (DIC). Folia Haematol 1977; 104: 874-8.
• 20 Sugimura D, Fukue H, Arai M, Matsumoto K, Fukutake K. Changes of factor XIII a and b subunit in patients with disseminated intravascular coagulation syndrome. Rinsho Byori 1996; 44: 355-61.
• 21 Asakura H, Shiratori Y, Jokaji H, Saito M, Uotani C, Kumabashiri I, Morishita E, Yamazaki M, Matsuda T. Changes in plasma levels of prothrombin fragment F1 + 2 in cases of disseminated intravascular coagulation. Acta Haematol 1993; 89: 22-5.
• 22 Asakura H, Ontachi Y, Mizutani T, Kato M, Saito M, Morishita E, Yamazaki M, Suga Y, Takami A, Miyamoto K, Nakao S. Elevated levels of free tissue factor pathway inhibitor antigen in cases of disseminated intravascular coagulation caused by various underlying diseases. Blood Coagul Fibrinolysis 2001; 12: 1-8.
• 23 Braat EA, Levi M, Bos R, Haverkate F, Lassen MR, de Maat MP, Rijken DC. Inactivation of single-chain urokinase-type plasminogen activator by thrombin in human subjects. J Lab Clin Med 1999; 134: 161-7.
• 24 Takahashi H, Wada K, Niwano H, Shibata A. Comparison of prothrombin fragment 1 + 2 with thrombin-antithrombin III complex in plasma of patients with disseminated intravascular coagulation. Blood Coagul Fibrinolysis 1992; 3: 813-8.
• 25 Sorensen JV, Rahr HB, Jensen HP, Borris LC, Lassen MR, Ejstrud P. Markers of coagulation and fibrinolysis after fractures of the lower extremities. Thromb Res 1992; 65: 479-86.
• 26 Baudo F, Caimi TM de, Cataldo F, Ravizza A, Arlati S, Casella G, Carugo D, Palareti G, Legnani C, Ridolfi L, Rossi R, D'Angelo A, Crippa L, Giudici D, Gallioli G, Wolfler A, Calori G. Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled dou- ble-blind, randomized, multicenter study. Intensive Care Med 1998; 24: 336-42.
• 27 Asakura H, Ontachi Y, Mizutani T, Kato M, Saito M, Morishita E, Yamazaki M, Aoshima K, Takami A, Yoshida T, Suga Y, Miyamoto K-I, Nakao S. Decreased plasma activity of antithrombin or protein C is not due to consumption coagulopathy in septic patients with disseminated intravascular coagulation. Eur J Haematol 2001; 67: 170-5.
• 28 Thorsen LI, Brosstad F, Gogstad G, Sletten K, Solum NO. Competitions between fibrinogen with its degradation products for interactions with the platelet-fibrinogen receptor. Thromb Res 1986; 44: 611-23.
• 29 Gaffney PJ. Fibrin Degradation Products: A Review of Structures Found in Vitro and in Vivo. Ann N Y Acad Sci 2001; 936: 594-610.
• 30 Raaphrost J, Groeneveld ABJ, Bossink AW, Hack CE. Early inhibition of activated fibrinolysis predicts microbial infection, shock and mortality in febrile medical patients. Thromb Haemost 2001; 86: 543-9.
• 31 Reis CV, Farsky SHP, Fernandes BL, Santoro ML, Oliva MLV, Mariano M Chudzinski-Tavassi AM. In Vivo Characterization of Lopap, a Prothrombin Activator Serine Protease from the Lonomia obliqua Caterpillar Venom. Thromb Res 2001; 102: 437-43.
• 32 Chudzinski-Tavassi AM, Schattner M, Fritzen M, Pozner RG, Reis CV, Lourenço D, Lazzari MA. Effects of lopap on human endothelial cells and platelets. Haemostasis 2001; 3: 257-65.
• 33 Hoffmeister HM, Szabo S, Kastner C, Beyer ME, Helber U, Kazmaier S, Wendel HP, Heller W, Seipel L. Thrombolytic therapy in acute myocardial infarction: comparison of procoagulant effects of strepkinase and alteplase regimens with focus on the kallikrein system and plasmin. Circulation 1998; 98: 2527-53.